Search This Blog

Wednesday, November 17, 2021

Pentagon sending medical teams to Minnesota hospitals amid surge in cases

 The Pentagon is sending emergency medical teams to major hospitals in Minnesota to relieve doctors as the state deals with a surge in coronavirus infections, Gov. Tim Walz (D) said Wednesday. 

The medical teams — each with 22 medical personnel — will arrive next week and immediately begin treating patients at the Hennepin County Medical Center and St. Cloud Hospital, Walz’s office said in a statement.

Walz said the teams will provide “an important measure of relief to the healthcare personnel who remain on the frontline of this crisis.”

“Every day, our doctors and nurses are treating Minnesotans sick with COVID-19 or suffering other emergencies. But they are under water, and they need all the help we can give them,” the governor said. “I’m grateful the Biden Administration heeded our request and is sending in reinforcements.”

The Hill has reached out to the Pentagon for further comment. 

The move comes as the state’s hospitals come under strain due to an influx of COVID-19 patients, the vast majority of which are unvaccinated. 

Over 1,300 residents are hospitalized for COVID-19, the highest the state has dealt with this year, and only 47 ICU beds are open statewide to patients, the statement said.

Meanwhile, Minnesota has one of the worst seven-day infection rates in the country, with data from the Centers for Disease Control and Prevention (CDC) showing the state has averaged about 490 cases per 100,000 residents.

Aside from the medical teams, Walz announced that a third skilled-nursing facility will act as a “transitional site” for patients who no longer need to be hospitalized but are not ready to go home.

A team of 25 medical staff—including 10 nurses from federal partners and 15 nursing assistants from the Minnesota National Guard and private vendors—will provide transitional care at he Cerenity Senior Care-Marian of Saint Paul for those who are currently hospitalized. 

https://thehill.com/policy/defense/581991-pentagon-sending-medical-teams-to-minnesota-hospitals-amid-surge-in-cases

Cardiovascular Systems cut to Hold by Needham

 From Buy

https://finviz.com/quote.ashx?t=csii&ty=c&ta=1&p=d

Hims & Hers to Offer its Health and Wellness Products in Amazon’s U.S. Store

 Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced it will start offering its products in Amazon’s store to increase the accessibility of Hims & Hers supplements, sexual health and wellness products and hair care offerings, including a few product bundles exclusively available through the new official Hims & Hers store on Amazon.com.

"We aim to meet digitally native consumers where they already are and create completely customer-centric health and wellness experiences for them," said Andrew Dudum, Chief Executive Officer and Co-Founder of Hims & Hers. "Having seen an increasing demand for our products on Amazon and having significantly expanded the availability of our products through new retail relationships over the last year, we are thrilled to also start selling in Amazon’s store. Doing so not only meets those consumer demands but also introduces our beautifully designed, science-backed, high quality wellness offerings to a whole new audience."

This will offer Amazon customers a variety of Hims & Hers personal care products including Hims & Hers’ top-selling biotin, immunity and sleep gummies, and collagen powder supplements; sexual health and wellness products, including Hims & Hers’ ring and wand vibrators and Hims’ climax delay spray; and hair care products, including Hers’ hair mask and scalp scrub. Amazon shoppers will also have exclusive access to 2-pack bundled offerings of Hims’ thickening shampoo and conditioner as well as Hers’ shampoo and conditioner.

https://finance.yahoo.com/news/hims-hers-offer-health-wellness-135700818.html

Eloxx Slumps As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors

 

  • Eloxx Pharmaceuticals Inc (NASDAQ: ELOXposted topline results from the monotherapy arms of its Phase 2 trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutation.

  • Eloxx delivered one-week ELX-02 data on 12 people with a G542X nonsense mutation who received ELX-02 at 1.5 mg/kg/day.

  • Sweat chloride, a biomarker of cystic fibrosis, fell by 5.4 mmol/L in recipients of ELX-02, causing the trial to meet one of its key secondary endpoints.

  • However, there was no change in lung function as measured by FEV1.

  • Eloxx attributed the missed FEV1 secondary endpoint to the short duration of the clinical trial.

  • The primary endpoints looked at safety and pharmacokinetics.

  • Eloxx said other groups did show short-term reductions in sweat chloride translate to long-term improvements in lung function.

  • Eloxx has begun dosing in a Phase 2 expansion arm, evaluating ELX-02 in combination with Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) Kalydeco, putting it on course to deliver data in 1H of 2022.

U.S. Plans to Invest Billions in Manufacturing COVID-19 Vaccine

 The United States plans to invest billions of dollars in expanding COVID-19 vaccine manufacturing capacity and make available an additional one billion doses per year, White House COVID-19 coordinator Jeff Zients said on Wednesday.

Activists have pressured President Joe Biden's administration to increase vaccine supply to poorer countries.

Zients said the government was preparing to offer makers of the mRNA vaccines substantial help to expand infrastructure and capacity, including facilities, equipment, staff or training.

Pfizer/BioNTech and Moderna are the only makers of mRNA vaccines, though Zients said subcontractors of those companies would also be included.

Zients said 80% of Americans 12 and older have received at least one COVID-19 vaccine dose, highlighting a milestone in efforts to curb the spread of the deadly virus.

He also said 2.6 million kids aged 5-11 will have received their first shot of the COVID-19 vaccine by the end of Wednesday.

https://www.usnews.com/news/top-news/articles/2021-11-17/us-plans-to-invest-billions-in-manufacturing-covid-19-vaccine

Edison: InMed Pharmaceuticals (INM): Progress Across the Business

 With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its commercial stage as BayMedica has been selling cannabichromene (CBC) in bulk. InMed has also advanced past the healthy volunteer stage in the INM-755 clinical program through the initiation of the INM-755 Phase II trial (755-201-EB) in up to 20 epidermolysis bullosa (EB) patients.

We have adjusted our valuation to US$290m or US$20.53 per basic share, from US$293m or US$24.24 per basic share. This is mainly due to a higher number of shares outstanding following the share issuance as a result of the closure of the BayMedica acquisition. In addition, there was a decline in net cash. InMed had US$15.4m in cash and marketable securities at 30 September 2021. We currently model an additional US$11m being raised in FY23, though the exact funding requirement will depend on the expense level for the combined companies. We will update our financial model once BayMedica financials are included in regulatory filings, which is likely to occur with the next quarterly report.

Click here to view the full report or here to sign up to receive research as it is published.

https://finance.yahoo.com/news/inmed-pharmaceuticals-inm-progress-across-132500247.html

AstraZeneca cardio med fast tracked in US

 AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA® (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK). The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need. This is being investigated in the ongoing Phase III DIALIZE-Outcomes trial.

HK is a prevalent condition in patients with chronic kidney disease (CKD) and heart failure (HF), affecting 24% to 48% of patients with moderate to advanced (stage 3-4) CKD and/or HF, and it remains a burden once patients are on chronic hemodialysis. In patients with end-stage renal disease (ESRD) receiving chronic hemodialysis, HK has been associated with an increased risk of all-cause and CV mortality, and hospitalizations.

https://finance.yahoo.com/news/lokelma-granted-fast-track-designation-150300177.html